Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer

被引：5
|
作者：
Takami, Hiroshi E. [1 ]
机构：
[1] Teikyo Univ, Sch Med, Dept Surg, Itabashi Ku, Tokyo 1738605, Japan
来源：
ENDOCRINE JOURNAL | 2011年 / 58卷 / 03期
关键词：
Molecularly targeted drugs; Kinase inhibitors; Differentiated thyroid carcinoma; Medullary thyroid carcinoma; PHASE-II TRIAL; SORAFENIB; CARCINOMA;
D O I：
10.1507/endocrj.K11E-076
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The prognosis of almost all thyroid cancers is good, but some patients have indications for these molecularly targeted. drugs. Some of these drugs, i.e., vandetanib, XL-184, sorafenib, motesanib, axitinib, and pazopanib, are clearly useful clinically.
引用
收藏
页码：151 / 153
页数：3
相关论文
共 50 条
  • [21] Targeted therapy for advanced gastric cancer: A review of current status and future prospects
    Kanat, Ozkan
    O'Neil, Bert
    Shahda, Safi
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2015, 7 (12) : 401 - 410
  • [22] Current status of chemotherapy for the treatment of advanced biliary tract cancer
    Sasaki, Takashi
    Isayama, Hiroyuki
    Nakai, Yousuke
    Koike, Kazuhiko
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2013, 28 (05) : 515 - 524
  • [23] Sunitinib for the treatment of thyroid cancer
    Gomez-Saez, Jose-Manuel
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (11) : 1345 - 1352
  • [24] Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice
    Masatoshi Kudo
    International Journal of Clinical Oncology, 2010, 15 : 242 - 255
  • [25] Targeted therapy in thyroid cancer: Towards a treatment card
    Lkhoyaali, S.
    Benhmida, S.
    Elhaj, M. Ait
    Layachi, M.
    Bensouda, Y.
    Errihani, H.
    PATHOLOGIE BIOLOGIE, 2015, 63 (01): : 1 - 6
  • [26] New Targeted Therapies for Thyroid Cancer
    Antonelli, Alessandro
    Fallahi, Poupak
    Ferrari, Silvia M.
    Ruffilli, Ilaria
    Santini, Francesca
    Minuto, Michele
    Galleri, David
    Miccoli, Paolo
    CURRENT GENOMICS, 2011, 12 (08) : 626 - 631
  • [27] Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)
    Capdevila, Jaume
    Manuel Trigo, Jose
    Aller, Javier
    Luis Manzano, Jose
    Garcia Adrin, Silvia
    Zafon Llopis, Carles
    Reig, Oscar
    Bohn, Uriel
    Ramon y Cajal, Teresa
    Duran-Poveda, Manuel
    Gonzalez Astorga, Beatriz
    Lopez-Alfonso, Ana
    Medina Martinez, Javier
    Porras, Ignacio
    Jose Reina, Juan
    Palacios, Nuria
    Grande, Enrique
    Cillan, Elena
    Matos, Ignacio
    Jose Grau, Juan
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2017, 177 (04) : 309 - 317
  • [28] Vandetanib: A novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer
    Ton, GiangThy N.
    Banaszynski, Megan E.
    Kolesar, Jill M.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (10) : 849 - 855
  • [29] Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives
    Shen, Ying-Chun
    Hsu, Chiun
    Cheng, Ann-Lii
    JOURNAL OF GASTROENTEROLOGY, 2010, 45 (08) : 794 - 807
  • [30] The current status of immunotherapy in the treatment of primary advanced and recurrent endometrial cancer
    Fontenot, Virginia E.
    Tewari, Krishnansu
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2023, 35 (01) : 34 - 42
12345